and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA ... granted restricted stock units with respect ...

We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently ... pevedotin plus Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in previously untreated (first ...

Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Since IPO, Disney stock has been traded on the New York Stock Exchange under the ticker symbol DIS, it has been one of the 30 stocks in the Dow Jones industrial average since 1991. Disney’s ...

Innovative Industrial Properties Inc. 9% Cum. Conv. Redeem. Pfd. Series A 0.35% Digital Realty Trust Inc. 5.25% Cum. Conv. Pfd. Series J-0.69% Digital Realty Trust Inc. 5.2% Cum. Redeem. Pfd ...

Jones Trading Maintains Buy on BrightSpire Capital, Maintains $7.25 Price Target Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage ...

This has some investors continuing to worry that the stock market in general might be overvalued. But there are always stocks that are cheaply priced. Below is a screen of stocks trading well ...

On-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company dev ...